Dr. Shiel received a Bachelor of Science degree with honors from the University of Notre Dame. There he was involved in research in radiation biology and received the Huisking Scholarship. After graduating from St. Louis University School of Medicine, he completed his Internal Medicine residency and Rheumatology fellowship at the University of California, Irvine. He is board-certified in Internal Medicine and Rheumatology.
Bullous pemphigoid can be chronic and mild without affecting the
general health of affected individuals. Treatment of bullous pemphigoid can resolve with topical cortisone
creams but sometimes requires high doses of cortisone ("steroids")
taken internally. Severe bullous pemphigoid can also require immune-suppression drugs such as azathioprine (Imuran). Tetracycline has been used as a treatment option. Other treatments that have been used for severe disease include intravenous immunoglobulin infusions, typically given monthly.
Recent research has indicated that large quantities of high-potency topical corticosteroids applied to the entire body surface were safer and more effective in controlling extensive bullous pemphigoid than oral corticosteroids. It was felt by the researchers that topical corticosteroids should now be the treatment of choice for bullous pemphigoid, particularly when the disease is not extensive.
Systemic lupus erythematosus is a condition characterized by chronic inflammation of body tissues caused by autoimmune disease. Lupus can cause disease of the skin, heart, lungs, kidneys, joints, and nervous
system. When only the skin is involved, the condition is called discoid lupus.
When internal organs are involved, the condition is called systemic lupus
erythematosus (SLE).